Pantecta Control

RSS
Withdrawn

This medicine's authorisation has been withdrawn

pantoprazole
Medicine Human Withdrawn
  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 19 September 2016, the European Commission withdrew the marketing authorisation for Pantecta Control (pantoprazole) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Takeda GmbH, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

Pantecta Control was granted marketing authorisation in the EU as an over-the-counter product on 12 June 2009 for the treatment of reflux symptoms (e.g. heartburn, acid regurgitation). The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2014. 

Pantecta Control was a duplicate application to Pantozol Control 20 mg gastro-resistant tablets, which is marketed in several EU countries. The marketing authorisation holder will maintain the marketing authorisation for Pantozol Control 20 mg gastro-resistant tablets and the remaining duplicates Controloc Control 20 mg gastro-resistant tablets, Somac Control 20 mg gastro-resistant tablets and Pantoloc Control 20 mg gastro-resistant tablets. 

The European Public Assessment Report (EPAR) for Pantecta Control is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (584.48 KB - PDF)

View

español (ES) (512.81 KB - PDF)

View

čeština (CS) (576.89 KB - PDF)

View

dansk (DA) (512.5 KB - PDF)

View

Deutsch (DE) (513.99 KB - PDF)

View

eesti keel (ET) (513.31 KB - PDF)

View

ελληνικά (EL) (584.2 KB - PDF)

View

français (FR) (514.66 KB - PDF)

View

italiano (IT) (536.62 KB - PDF)

View

latviešu valoda (LV) (552.19 KB - PDF)

View

lietuvių kalba (LT) (558.54 KB - PDF)

View

magyar (HU) (549.7 KB - PDF)

View

Malti (MT) (555.41 KB - PDF)

View

Nederlands (NL) (512.93 KB - PDF)

View

polski (PL) (577.87 KB - PDF)

View

português (PT) (513.19 KB - PDF)

View

română (RO) (559.28 KB - PDF)

View

slovenčina (SK) (576.32 KB - PDF)

View

slovenščina (SL) (566.92 KB - PDF)

View

Suomi (FI) (513 KB - PDF)

View

svenska (SV) (535.02 KB - PDF)

View

Product information

български (BG) (1.01 MB - PDF)

View

español (ES) (703.94 KB - PDF)

View

čeština (CS) (830.86 KB - PDF)

View

dansk (DA) (779.67 KB - PDF)

View

Deutsch (DE) (747.37 KB - PDF)

View

eesti keel (ET) (710.15 KB - PDF)

View

ελληνικά (EL) (855.12 KB - PDF)

View

français (FR) (1.06 MB - PDF)

View

hrvatski (HR) (875.24 KB - PDF)

View

íslenska (IS) (812.57 KB - PDF)

View

italiano (IT) (846.87 KB - PDF)

View

latviešu valoda (LV) (919.86 KB - PDF)

View

lietuvių kalba (LT) (844.2 KB - PDF)

View

magyar (HU) (955.3 KB - PDF)

View

Malti (MT) (884.2 KB - PDF)

View

Nederlands (NL) (712.71 KB - PDF)

View

norsk (NO) (691.29 KB - PDF)

View

polski (PL) (838.71 KB - PDF)

View

português (PT) (752.54 KB - PDF)

View

română (RO) (787.92 KB - PDF)

View

slovenčina (SK) (1.01 MB - PDF)

View

slovenščina (SL) (900.92 KB - PDF)

View

Suomi (FI) (729.76 KB - PDF)

View

svenska (SV) (776.59 KB - PDF)

View
Latest procedure affecting product information:IG/0634
19/09/2016
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (520.33 KB - PDF)

View

español (ES) (460 KB - PDF)

View

čeština (CS) (485.81 KB - PDF)

View

dansk (DA) (12.5 KB - PDF)

View

Deutsch (DE) (459.21 KB - PDF)

View

eesti keel (ET) (459.66 KB - PDF)

View

ελληνικά (EL) (517.23 KB - PDF)

View

français (FR) (459.89 KB - PDF)

View

italiano (IT) (459.36 KB - PDF)

View

latviešu valoda (LV) (515.05 KB - PDF)

View

lietuvių kalba (LT) (503.17 KB - PDF)

View

magyar (HU) (504.28 KB - PDF)

View

Malti (MT) (511.13 KB - PDF)

View

Nederlands (NL) (459.79 KB - PDF)

View

polski (PL) (508 KB - PDF)

View

português (PT) (459.34 KB - PDF)

View

română (RO) (490.38 KB - PDF)

View

slovenčina (SK) (487.09 KB - PDF)

View

slovenščina (SL) (471.21 KB - PDF)

View

Suomi (FI) (459.07 KB - PDF)

View

svenska (SV) (459.85 KB - PDF)

View

Product details

Name of medicine
Pantecta Control
Active substance
pantoprazole
International non-proprietary name (INN) or common name
pantoprazole
Therapeutic area (MeSH)
Gastroesophageal Reflux
Anatomical therapeutic chemical (ATC) code
A02BC02

Pharmacotherapeutic group

Proton pump inhibitors

Therapeutic indication

Short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults.

Authorisation details

EMA product number
EMEA/H/C/001099
Marketing authorisation holder
Takeda GmbH

Byk-Gulden-Strasse 2
D-78467 Konstanz
Germany

Marketing authorisation issued
12/06/2009
Withdrawal of marketing authorisation
19/09/2016
Revision
7

Assessment history

This page was last updated on

Share this page